Am I eligible?

You may be eligible if you are:

  • A resident of the United States
  • A pregnant woman diagnosed with plaque psoriasis who has:
    • Used SKYRIZI® (risankizumab-rzaa) during pregnancy or just prior to pregnancy (within 20 weeks prior to conception)
    • Used other similar medications for plaque psoriasis during pregnancy or just prior to pregnancy*

*Please note: If you have used plaque psoriasis medications other than risankizumab, such as TNF inhibitors, IL-17 inhibitors, IL-12/23 inhibitors, or other IL-23 inhibitors, you may be eligible to participate. These medications include Stelara (ustekinumab), Cosentyx (secukinumab), Siliq (brodalumab), Taltz (ixekizumab), Tremfya (guselkumab), Ilumya (tildrakizumab), Enbrel (etanercept) or biosimilar (Erelzi, Eticovo), Remicade (infliximab) or biosimilar (Avsola, Inflectra, Ixifi, Renflexis), Humira (adalimumab) or biosimilar (Abrilada, Amjevita, Cyltezo, Hadlima, Hulio, Hyrimoz), or Cimzia (certolizumab). If you have used any of these medications during or just prior to pregnancy, the registry staff can help determine your eligibility.

Third-party trademarks used herein are trademarks of their respective owners.

Contact request form

Complete this form and a registry team member will contact you with more information about participating in the Registry.

* marks required field.

I authorize the GLOW Pregnancy Registry to contact me and/or leave a message for me at these numbers or to contact me via email at the address listed below. I agree to the Registry referencing the GLOW Pregnancy Registry in messages or emails.

The registry is open from 8.30 am – 5.00 pm ET Monday-Friday

Privacy Statement:

Pharmaceutical Product Development, LLC. (PPD) respects your privacy and understands that it is important to you. The information you provide on this form will be used to contact you for the purposes of assessing your eligibility to participate in the GLOW Pregnancy Registry. This information will be held by PPD and not shared with the study sponsor (AbbVie Clinical Development Operations) or any other third party without your permission. In the event you choose not to enroll, Registry staff will request permission to share your contact information with Propharma (a safety vendor hired by AbbVie Clinical Development Operations), in order for them to contact you for safety follow up about your pregnancy. If you do not provide permission, and do not enroll in the Registry your contact details will be deleted.